Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease.
COVID-19
epidemiology
global health
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
20
11
2020
revised:
01
02
2021
accepted:
19
03
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
15
4
2021
Statut:
ppublish
Résumé
History of cardiovascular diseases (CVDs) may influence the prognosis of patients hospitalised for COVID-19. We investigated whether patients with previous CVD have increased risk of death and major adverse cardiovascular event (MACE) when hospitalised for COVID-19. We included 839 patients with COVID-19 hospitalised at the University Hospitals of Geneva. Demographic characteristics, medical history, laboratory values, ECG at admission and medications at admission were collected based on electronic medical records. The primary outcome was a composite of in-hospital mortality or MACE. Median age was 67 years, 453 (54%) were males and 277 (33%) had history of CVD. In total, 152 (18%) died and 687 (82%) were discharged, including 72 (9%) who survived a MACE. Patients with previous CVD were more at risk of composite outcomes 141/277 (51%) compared with those without CVD 83/562 (15%) (OR=6.0 (95% CI 4.3 to 8.4), p<0.001). Multivariate analyses showed that history of CVD remained an independent risk factor of in-hospital death or MACE (OR=2.4; (95% CI 1.6 to 3.5)), as did age (OR for a 10-year increase=2.2 (95% CI 1.9 to 2.6)), male gender (OR=1.6 (95% CI 1.1 to 2.3)), chronic obstructive pulmonary disease (OR=2.1 (95% CI 1.0 to 4.2)) and lung infiltration associated with COVID-19 at CT scan (OR=1.9 (95% CI 1.2 to 3.0)). History of CVD (OR=2.9 (95% CI 1.7 to 5)), age (OR=2.5 (95% CI 2.0 to 3.2)), male gender (OR=1.6 (95% CI 0.98 to 2.6)) and elevated C reactive protein (CRP) levels on admission (OR for a 10 mg/L increase=1.1 (95% CI 1.1 to 1.2)) were independent risk factors for mortality. History of CVD is associated with higher in-hospital mortality and MACE in hospitalised patients with COVID-19. Other factors associated with higher in-hospital mortality are older age, male sex and elevated CRP on admission.
Identifiants
pubmed: 33833064
pii: openhrt-2020-001526
doi: 10.1136/openhrt-2020-001526
pmc: PMC8039226
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Eur Heart J. 2020 Jun 7;41(22):2070-2079
pubmed: 32391877
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
J Med Virol. 2020 Oct;92(10):1915-1921
pubmed: 32293753
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
J Biol Regul Homeost Agents. 2020 Apr 07;34(2):339-343
pubmed: 32253888
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
Eur Heart J. 2020 May 14;41(19):1798-1800
pubmed: 32186331
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
R I Med J (2013). 2020 Jun 19;103(6):39-43
pubmed: 32570995
Nat Rev Nephrol. 2020 Jun;16(6):305-307
pubmed: 32246101
JAMA. 2020 Aug 25;324(8):799-801
pubmed: 32702090
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Eur Heart J Cardiovasc Pharmacother. 2021 Mar 15;7(2):148-157
pubmed: 32542337